Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Aorui Technology

Explore full profile

Microfluidic solutions for precision diagnostics and personalized medicine

ChinaFounded 2018Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2025
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Shanghai Aorui Technology and the history behind them.

About Shanghai Aorui Technology

Shanghai Aurefluidics Technology Co., Ltd. is at the forefront of intelligent microfluidic product development, specializing in cutting-edge MEMS (Micro-Electro-Mechanical Systems) microfluidic chip design technology. The company's expertise encompasses digital droplet, digital atomization, and digital micropump technologies, all protected by proprietary intellectual property rights. Leveraging the 8-inch MEMS process line at the Shanghai Institute of Microsystem and Information Technology, Aurefluidics has established comprehensive capabilities in design, manufacturing, testing, and service. Their core technologies include CMOS-MEMS inkjet printing chip design processes, whole-chip microfluidic channel design, cell printing and manipulation techniques, integrated closed-loop temperature control, microfluidic process design, and system integration. Aurefluidics' innovative solutions find wide-ranging applications in pharmaceutical research and development, precision diagnostics, and targeted therapies. The company's product portfolio caters to various fields, including biological printing, industrial printing, and consumer printing applications. By offering one-stop printing development solutions, Aurefluidics aims to provide clients with high-performance, reliable, and stable intelligent microfluidic products. The company's technology has significant implications for disease diagnosis, personalized treatment, and various biotechnology applications. These include monoclonal screening for research and production strains, construction of diagnostic and detection antibody cell lines, single-clone screening of pluripotent stem cells and gene-edited cell lines, and monoclonal screening for antibody, vaccine, and recombinant protein production cells. Aurefluidics' solutions also extend to single-cell transcriptomics, proteomics, and multi-omics studies, as well as tumor heterogeneity analysis. Their technology supports the development of cell lines for research purposes and virus vector production. Additionally, the company's products find applications in allergy and inflammation detection, immune and infection testing, cardiovascular health assessment, agricultural applications, medical diagnostics, biochip preparation, and food safety testing.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
China
Open positions
None listed
Dealroom signal
19.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, Microfluidics, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Links
Website

Latest news

Press, funding announcements and product moves mentioning Shanghai Aorui Technology.

See all news

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BEquity / VC Jan 2025 $14M $55M Sitri · Xingcheng Capital
SPINOUTOther financing Jan 2018 $0 SITRI
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Aorui Technology website traffic

Latest recorded traffic for Shanghai Aorui Technology is 20 monthly website visits, down 99.7% over the last three months.

Latest monthly visits20 3-month web change-99.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Xingcheng Capital
  • Sitri
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Aorui Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Aorui Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.